Urinary Monocyte Chemoattractant Protein and Lupus Nephritis Activity
|Sabah Alharazy1*, Norella CT Kong1, Marlyn Mohd2, Shamsul A Shah3, Arbaiyah Báin1 and Abdul Halim Abdul Gafor1|
|1Nephrology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia|
|2Department of Medical Microbiology & Immunology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia|
|3Department of Community Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia|
|Corresponding Author :||Dr. Sabah Mohamed Alharazy
Nephrology Unit, Department of Medicine
Pusat Perubatan Universiti Kebangsaan Malaysia
Jalaln Yaacob Latif, Bandar Tun Razak
56000 Cheras, Kuala Lumpur, Malaysia
E-mail: [email protected]
|Received December 03, 2013; Accepted January 20, 2014; Published January 28, 2014|
|Citation: Alharazy S, Kong NCT, Mohd M, Shah SA, Báin A, et al. (2014) Urinary Monocyte Chemoattractant Protein and Lupus Nephritis Activity. J Clin Cell Immunol 5:187. doi:10.4172/2155-9899.1000187|
|Copyright: © 2014 Alharazy S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Objective: Monocyte chemoattractant protein-1 (MCP-1) is reported to be associated with lupus nephritis (LN) activity. We therefore investigated urinary MCP-1 (uMCP-1) in patients with biopsy proven LN.
Methods: This was a cross-sectional observational study in which uMCP-1 levels and the standard parameters of LN activity were measured in these patients.
Results: One hundred patients were recruited: 47 with active and 53 inactive LN. uMCP-1 levels were increased in those with active LN [9,317.5 pg/mg creatinine (5,48.3-40,170)] compared to those with inactive LN [3,682 pg/ mg creatinine (0-23,866)] (p<0.001). uMCP-1 correlated with proteinuria (r=0.39, p=0.001), serum albumin (r=-0.35, p=0.001) and SLEDAI-2K (renal) (r=0.39, p=0.001). Area under receiver operating characteristic (AUROC) curve for uMCP-1 was 0.82 (p=0.001) compared with 0.50 (p=0.95), 0.37 (p=0.50), 0.43 (p=0.26) for anti-ds-DNA Ab, C3 and C4 respectively. AUROC for proteinuria was 0.94 (p<0.001) and for SLEDAI-2K (renal) was 0.96 (p<0.001). Only proteinuria and SLEDAI-2K (renal) were independent predictors of LN activity.
Conclusions: uMCP-1 may provide further adjunctive evidence if the clinical diagnosis of LN activity remains uncertain and facilitate improved grading of renal disease activity in this complex disease thus leading to improved treatment and outcome. Serial measurements of uMCP-1 are indicated.